NasdaqCM · Biotechnology

Lisata Therapeutics (LSTA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Hold

Ratings unavailable

$1.55+0.43 (+38.4%)Latest market snapshot · Yahoo Finance

Market cap$14.0M

Cash$10.4M

Quarterly burn$2.6M

Pipeline assets12

Short float0.8%

Clinical portfolio

Lisata Therapeutics Drug Pipeline

Showing 1 of 12

Asset	Indication	Stage	Milestone	Signals ?
LSTA1 + gemcitabine/nab-paclitaxel	Pancreatic cancer	Phase 1/2	Dec 31, 2026	—

Continue with BioPharma ProUnlock 11 additional programs and complete development details.

Unlock Pro

Upcoming milestones

LSTA Catalyst Timeline

1 currently tracked

Dec 31, 2026

LSTA1 + gemcitabine/nab-paclitaxel

Phase 1/2

Pancreatic cancer

Data readout

Event details

Company profile

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.